Get the Stockscreener App
1.18
18.89%
-0.62
Orgenesis Inc stock is traded at $1.18, with a volume of 2,014.
It is down -18.89% in the last 24 hours and down -73.27% over the past month.
See More
Previous Close:
$1.80
Open:
$1.16
24h Volume:
2,014
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
$662.00K
Net Income/Loss:
$-29.02M
P/E Ratio:
-0.1388
EPS:
-8.5
Net Cash Flow:
$-12.54M
1W Performance:
-18.89%
1M Performance:
-73.27%
6M Performance:
-76.19%
1Y Performance:
-86.10%
1-Day Range:
$1.15
$1.25
1-Week Range:
$1.15
$1.25
52-Week Range:
$1.15
$1.25
Orgenesis Inc Stock (ORGS) Company Profile
Compare ORGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORGS
Orgenesis Inc
|
1.18 | 0 | 662.00K | -29.02M | -12.54M | -8.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Orgenesis Inc Stock (ORGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-18 | Initiated | Dawson James | Buy |
Orgenesis Inc Stock (ORGS) Latest News
Orgenesis Inc. Secures $5 Million Equity Investment, Moves Trading to OTCQXOrgenesis Inc. (NASDAQ: ORGS) recently entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, a Nevada limited liability company. As per the agre - Defense World
Analysts’ Weekly Ratings Updates for Blueprint Medicines (BPMC) - Defense World
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings - StockTitan
Orgenesis (NASDAQ:ORGS) Stock Price Down 13.1% – What’s Next? - Defense World
UBS Group Lowers YETI (NYSE:YETI) Price Target to $43.00 - Defense World
Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry - News & Insights
Orgenesis announces director resignation By Investing.com - Investing.com Canada
Orgenesis announces director resignation - Investing.com
Stromal Vascular Fraction Market Growth Projections: Surpassing USD 280.1 Billion by 2034 - openPR
Critical Contrast: Orgenesis (NASDAQ:ORGS) vs. BridgeBio Pharma (NASDAQ:BBIO) - Defense World
Viral Vector Production (Research-use) Market Size to Hit USD 7.62 Bn by 2034 - BioSpace
Autologous Stem Cell and Non-Stem Cell-Based Therapies Market Opportunity Analysis and Forecast, 2024-2030 - openPR
Orgenesis Inc. sees insider transactions totaling $16,259 in sales By Investing.com - Investing.com Nigeria
Orgenesis Inc. sees insider transactions totaling $16,259 in sales - Investing.com
GLP-1 Receptor Agonist Market Overall Study Report 2024-2031 | - openPR
7 Companies Owned by Pfizer - Investopedia
3D Bioprinting for Tissue and Organ Regeneration Market to Reach $424.3 Million by 2030 As Revealed In New ... - WhaTech
Orgenesis Inc. Reports Q3 2024 Financial Results - TipRanks
Common Warts Treatment Market Trade Analysis and Statistical - openPR
Orgenesis Provides Third Quarter 2024 Business Update - The Manila Times
Analysts Set Boralex Inc. (TSE:BLX) Target Price at C$43.50 - Defense World
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
Adeia (NASDAQ:ADEA) Trading Up 4.8% After Dividend Announcement - Defense World
Lassonde Industries (TSE:LAS) Cut to Hold at National Bank Financial - Defense World
Mastech Digital Reports Year-Over-Year Revenue Growth and Record Gross Margins in Third Quarter 2024 - Defense World
StockNews.com Upgrades Paramount Global (NASDAQ:PARA) to “Hold” - Defense World
Fulgent Genetics (NASDAQ:FLGT) Rating Lowered to “Sell” at StockNews.com - Defense World
Osisko Gold Royalties (NYSE:OR) Stock Rating Lowered by TD Securities - Defense World
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World
Vishay Intertechnology, Inc. Announces Financial Results for Fiscal Quarter and Nine Fiscal Months Ending September 28, 2024Vishay Intertechnology, Inc. (NYSE: VSH) released its financial results for the fiscal quarter and nine fiscal months concludi - Defense World
Superior Group of Companies Announces Quarterly Results and Investor Presentation - Defense World
News (NASDAQ:NWSA) Stock Rating Lowered by StockNews.com - Defense World
UBS Group Downgrades Teck Resources (TSE:TCK) to Hold - Defense World
Contrasting Standard Lithium (NYSE:SLI) & Chemours (NYSE:CC) - Defense World
ASOS Plc (LON:ASC) Insider José Antonio Ramos Calamonte Sells 1,991 Shares of Stock - Defense World
Logiq Inc. Enters Stock Purchase Agreement With EviMate LLC - Defense World
Invesco BulletShares 2027 High Yield Corporate Bond ETF (NASDAQ:BSJR) Short Interest Update - Defense World
Orgenesis Inc. Faces Delisting from Nasdaq, Elects New Board Members - Defense World
Orgenesis Expands Board with Three New Appointments - TipRanks
Sanford C. Bernstein Cuts Confluent (NASDAQ:CFLT) Price Target to $33.00 - Defense World
Financial Review: Appen (OTCMKTS:APPEF) & NCR Voyix (NYSE:VYX) - Defense World
Orgenesis Inc. announces director resignation, remains advisor By Investing.com - Investing.com Australia
Orgenesis Inc. announces director resignation, remains advisor - Investing.com India
Biotech Alert: Searches spiking for these stocks today - TipRanks
Orgenesis Commences Trading on OTCQX® Best Market - StockTitan
Don’t rule out Hyundai selling Kia or Genesis to Toyota - AutoExpress
United States shares higher at close of trade; Dow Jones Industrial Average up 0.09% - Investing.com India
Orgenesis stock hits 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.09% - Investing.com
Dow Falls Over 100 Points; Netflix Posts Upbeat Results - Benzinga
Orgenesis stock hits 52-week low at $1.95 amid market challenges - Investing.com
Orgenesis Inc Stock (ORGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Cap:
|
Volume (24h):